Diagnosis and management of chronic myeloid leukemia: A survey of American and European practice patterns

Hagop M. Kantarjian, Jorge Cortes, François Guilhot, Andreas Hochhaus, Michele Baccarani, Lee Lokey

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has brought new challenges; these include optimizing disease monitoring, imatinib resistance, and use of novel, more potent tyrosine kinase inhibitors. Thus, there is a need to establish new best practices for CML management in the post-imatinib era. METHODS. An internet-based questionnaire, consisting of 26 multiple choice questions, was developed to assess hematologists' and oncologists' self-reported treatment strategies for CML. RESULTS. Between November 2005 and January 2006, 956 eligible physicians responded to the survey; 727 from the US and 229 from Europe. Most US respondents (60%) practiced in the community setting, whereas European respondents were primarily academic (44%) and hospital-based (40%). Physicians' responses were generally in line with current recommendations, although differences were identified. Confusion existed among respondents over optimal timing of treatment decisions, with a notable proportion of physicians focusing on a single timepoint rather than consistent monitoring, as currently advocated. Some respondents were unaware of new molecular monitoring techniques, when to monitor for BCR-ABL mutations (and the impact on treatment decisions), and the benefit of new tyrosine kinase inhibitors. CONCLUSIONS. Responses to the survey suggest that treatment practices in some areas of CML management are not in line with current recommendations. Identified areas of need should be targeted in future educational activities for the CML community.

Original languageEnglish (US)
Pages (from-to)1365-1375
Number of pages11
JournalCancer
Volume109
Issue number7
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Physicians
Protein-Tyrosine Kinases
Therapeutics
Surveys and Questionnaires
Practice Guidelines
Internet
Education
Mutation
Imatinib Mesylate

Keywords

  • BCR-ABL mutation
  • Clinical practice
  • CML
  • Dasatinib
  • Imatinib
  • Molecular monitoring
  • Survey

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Diagnosis and management of chronic myeloid leukemia : A survey of American and European practice patterns. / Kantarjian, Hagop M.; Cortes, Jorge; Guilhot, François; Hochhaus, Andreas; Baccarani, Michele; Lokey, Lee.

In: Cancer, Vol. 109, No. 7, 01.04.2007, p. 1365-1375.

Research output: Contribution to journalArticle

Kantarjian, HM, Cortes, J, Guilhot, F, Hochhaus, A, Baccarani, M & Lokey, L 2007, 'Diagnosis and management of chronic myeloid leukemia: A survey of American and European practice patterns', Cancer, vol. 109, no. 7, pp. 1365-1375. https://doi.org/10.1002/cncr.22523
Kantarjian, Hagop M. ; Cortes, Jorge ; Guilhot, François ; Hochhaus, Andreas ; Baccarani, Michele ; Lokey, Lee. / Diagnosis and management of chronic myeloid leukemia : A survey of American and European practice patterns. In: Cancer. 2007 ; Vol. 109, No. 7. pp. 1365-1375.
@article{d1a4ec822b1445b8868d0d9284cfd5a9,
title = "Diagnosis and management of chronic myeloid leukemia: A survey of American and European practice patterns",
abstract = "BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has brought new challenges; these include optimizing disease monitoring, imatinib resistance, and use of novel, more potent tyrosine kinase inhibitors. Thus, there is a need to establish new best practices for CML management in the post-imatinib era. METHODS. An internet-based questionnaire, consisting of 26 multiple choice questions, was developed to assess hematologists' and oncologists' self-reported treatment strategies for CML. RESULTS. Between November 2005 and January 2006, 956 eligible physicians responded to the survey; 727 from the US and 229 from Europe. Most US respondents (60{\%}) practiced in the community setting, whereas European respondents were primarily academic (44{\%}) and hospital-based (40{\%}). Physicians' responses were generally in line with current recommendations, although differences were identified. Confusion existed among respondents over optimal timing of treatment decisions, with a notable proportion of physicians focusing on a single timepoint rather than consistent monitoring, as currently advocated. Some respondents were unaware of new molecular monitoring techniques, when to monitor for BCR-ABL mutations (and the impact on treatment decisions), and the benefit of new tyrosine kinase inhibitors. CONCLUSIONS. Responses to the survey suggest that treatment practices in some areas of CML management are not in line with current recommendations. Identified areas of need should be targeted in future educational activities for the CML community.",
keywords = "BCR-ABL mutation, Clinical practice, CML, Dasatinib, Imatinib, Molecular monitoring, Survey",
author = "Kantarjian, {Hagop M.} and Jorge Cortes and Fran{\cc}ois Guilhot and Andreas Hochhaus and Michele Baccarani and Lee Lokey",
year = "2007",
month = "4",
day = "1",
doi = "10.1002/cncr.22523",
language = "English (US)",
volume = "109",
pages = "1365--1375",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Diagnosis and management of chronic myeloid leukemia

T2 - A survey of American and European practice patterns

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge

AU - Guilhot, François

AU - Hochhaus, Andreas

AU - Baccarani, Michele

AU - Lokey, Lee

PY - 2007/4/1

Y1 - 2007/4/1

N2 - BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has brought new challenges; these include optimizing disease monitoring, imatinib resistance, and use of novel, more potent tyrosine kinase inhibitors. Thus, there is a need to establish new best practices for CML management in the post-imatinib era. METHODS. An internet-based questionnaire, consisting of 26 multiple choice questions, was developed to assess hematologists' and oncologists' self-reported treatment strategies for CML. RESULTS. Between November 2005 and January 2006, 956 eligible physicians responded to the survey; 727 from the US and 229 from Europe. Most US respondents (60%) practiced in the community setting, whereas European respondents were primarily academic (44%) and hospital-based (40%). Physicians' responses were generally in line with current recommendations, although differences were identified. Confusion existed among respondents over optimal timing of treatment decisions, with a notable proportion of physicians focusing on a single timepoint rather than consistent monitoring, as currently advocated. Some respondents were unaware of new molecular monitoring techniques, when to monitor for BCR-ABL mutations (and the impact on treatment decisions), and the benefit of new tyrosine kinase inhibitors. CONCLUSIONS. Responses to the survey suggest that treatment practices in some areas of CML management are not in line with current recommendations. Identified areas of need should be targeted in future educational activities for the CML community.

AB - BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has brought new challenges; these include optimizing disease monitoring, imatinib resistance, and use of novel, more potent tyrosine kinase inhibitors. Thus, there is a need to establish new best practices for CML management in the post-imatinib era. METHODS. An internet-based questionnaire, consisting of 26 multiple choice questions, was developed to assess hematologists' and oncologists' self-reported treatment strategies for CML. RESULTS. Between November 2005 and January 2006, 956 eligible physicians responded to the survey; 727 from the US and 229 from Europe. Most US respondents (60%) practiced in the community setting, whereas European respondents were primarily academic (44%) and hospital-based (40%). Physicians' responses were generally in line with current recommendations, although differences were identified. Confusion existed among respondents over optimal timing of treatment decisions, with a notable proportion of physicians focusing on a single timepoint rather than consistent monitoring, as currently advocated. Some respondents were unaware of new molecular monitoring techniques, when to monitor for BCR-ABL mutations (and the impact on treatment decisions), and the benefit of new tyrosine kinase inhibitors. CONCLUSIONS. Responses to the survey suggest that treatment practices in some areas of CML management are not in line with current recommendations. Identified areas of need should be targeted in future educational activities for the CML community.

KW - BCR-ABL mutation

KW - Clinical practice

KW - CML

KW - Dasatinib

KW - Imatinib

KW - Molecular monitoring

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=33947496833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947496833&partnerID=8YFLogxK

U2 - 10.1002/cncr.22523

DO - 10.1002/cncr.22523

M3 - Article

C2 - 17326047

AN - SCOPUS:33947496833

VL - 109

SP - 1365

EP - 1375

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -